White & Case advises Takeda on asset sale to Hikma and Esteve
White & Case advised pharmaceutical multinational Takeda in connection with two distinct operations.
The first matter sees Takeda involved as the seller of a pharmaceutical products portfolio, currently licensed to Hikma Pharmaceuticals. The buyer currently holds product commercialisation rights across the portfolio for certain territories in the MENA region.
The second operation is the sale of Takeda’s oncological product “MEPACT” to Esteve Pharmaceutical.
Both transactions are expected to conclude before the end of 2025, being subject to standard suspensive conditions and antitrust approvals proceedings.
The parties
Headquarterd in Japan, Takeda is a globally active pharmaceutical company. Its range of specialisation spans gastroenterology, rare diseases, plasma derived therapies, oncology and neuroscience
Hikma is a British pharmaceutical multinational, listed on the London Stock Exchange and globally present across North America, MENA, and Europe.
Barcelona-based Esteve is an international pharmaceutical company with operational presence across Spain, Portugal, Germany, France, and the United Kingdom.
The team
Partners Michael Immordino (London and Milan, pictured left) and Leonardo Graffi (Milan and London, pictured right) co-led the international White & Case team on both transactions, working alongside partners Philip Trillmich (Frankfurt) and Strati Sakellariou-Witt (Brussels). Brussels-based associates Tommaso Poli and Giulio Preti further contributed to the effort.
